1. Home
  2. GNPX vs SYRS Comparison

GNPX vs SYRS Comparison

Compare GNPX & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • SYRS
  • Stock Information
  • Founded
  • GNPX 2009
  • SYRS 2011
  • Country
  • GNPX United States
  • SYRS United States
  • Employees
  • GNPX N/A
  • SYRS N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • SYRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNPX Health Care
  • SYRS Health Care
  • Exchange
  • GNPX Nasdaq
  • SYRS Nasdaq
  • Market Cap
  • GNPX 6.1M
  • SYRS 7.1M
  • IPO Year
  • GNPX 2018
  • SYRS 2016
  • Fundamental
  • Price
  • GNPX $0.75
  • SYRS $0.21
  • Analyst Decision
  • GNPX Strong Buy
  • SYRS Hold
  • Analyst Count
  • GNPX 1
  • SYRS 5
  • Target Price
  • GNPX $10.00
  • SYRS $3.00
  • AVG Volume (30 Days)
  • GNPX 367.1K
  • SYRS 3.2M
  • Earning Date
  • GNPX 11-13-2024
  • SYRS 10-31-2024
  • Dividend Yield
  • GNPX N/A
  • SYRS N/A
  • EPS Growth
  • GNPX N/A
  • SYRS N/A
  • EPS
  • GNPX N/A
  • SYRS N/A
  • Revenue
  • GNPX N/A
  • SYRS $386,000.00
  • Revenue This Year
  • GNPX N/A
  • SYRS N/A
  • Revenue Next Year
  • GNPX N/A
  • SYRS N/A
  • P/E Ratio
  • GNPX N/A
  • SYRS N/A
  • Revenue Growth
  • GNPX N/A
  • SYRS N/A
  • 52 Week Low
  • GNPX $0.28
  • SYRS $0.18
  • 52 Week High
  • GNPX $13.00
  • SYRS $7.96
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 40.74
  • SYRS 36.45
  • Support Level
  • GNPX $0.66
  • SYRS $0.20
  • Resistance Level
  • GNPX $0.74
  • SYRS $0.25
  • Average True Range (ATR)
  • GNPX 0.06
  • SYRS 0.03
  • MACD
  • GNPX 0.00
  • SYRS 0.03
  • Stochastic Oscillator
  • GNPX 35.04
  • SYRS 11.73

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SYRS Syros Pharmaceuticals Inc.

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Share on Social Networks: